Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation
Glossary on
Printer Friendly Page A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or  AXIN1 Mutation

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation identifier:

Treatment study for people with advanced cancer with an APC or AXIN1 mutation

Study Contact Information:

Study Contact: Recursion Pharmaceuticals
By phone: 385-374-1724
By email:

Tempus Labs
Study Contact:

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation

About the Study

This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or cancers with an APC or AXIN1 mutation. REC-4881 is a type of drug known as a MEK1/2 inhibitor. 

What the Study Involves

Participants will be assigned to one of two groups based on the results of tumor testing. All participants will receive the drug REC-4881.

  • Group 1: tumors with AXIN1 mutations
  • Group 2: tumors with APC mutations (this may include people with an inherited APC mutation and/or a type of inherited syndrome known as Familial Adenomatous Polyposis (FAP or AFAP) 

Participants will take REC-4881 once daily by mouth for up to 2 years. Follow up will include office visits, lab tests and imaging to track response to the treatment. 

Study Locations

Note: For all study locations, the contact is:


  • Yuma, AZ
    Yuma Regional Medical Center


  • Springdale, AR
    Highlands Oncology


  • Cerritos, CA
    TOI Clinical Research
  • Fullerton, CA
    Providence Medical Foundation (Fullerton)
  • Long Beach, CA
  • Los Alamitos, CA
    Cancer and Blood Research Center
  • San Diego, CA
    Sharp HealthCare
  • Santa Barbara, CA
    Ridley-Tree Cancer Center
  • Santa Rosa, CA
    Providence Medical Foundation (Santa Rosa)


  • Norwich, CT
    Eastern Connecticut Hematology & Oncology Associates


  • Fort Lauderdale, FL
    Holy Cross Hospital
  • Jacksonville, FL
    Cancer Specialists of North Florida
  • Lakeland, FL
    TOI Florida


  • Athens, GA
    University Cancer & Blood Center


  • Hinsdale, IL
    Hope and Healing Cancer Services
  • Rolling Meadows, IL
    Northwest Oncology & Hematology


  • Fort Wayne, IN
     Fort Wayne Medical Oncology and Hematology
  • Indianapolis, IN
    Community Health Network


  • Baton Rouge, LA
    Our Lady of the Lake


  • Germantown, MD
    The Center for Cancer and Blood Disorders


  • Fairhaven, MA
    Southcoast Centers for Cancer Care


  • Saint Joseph, MO
    Mosaic Life Care


  • Omaha, NE
    Nebraska Cancer Specialists


  • Las Vegas, NV
    OptumCare Cancer Care
  • Las Vegas, NV
    Comprehensive Cancer Centers of Nevada

New Jersey

  • Belleville, NJ
    New Jersey Cancer Care
  • Englewood, NJ
    Englewood Health
  • Florham Park, NJ
    Summit Medical Group

New York

  • East Syracuse, NY

North Dakota

  • Fargo, ND
    Sanford Health - Fargo


  • Canton, OH
    Aultman Medical Group
  • Cincinnati, OH
    TriHealth Cancer Institute
  • Toledo, OH
    The Toledo Clinic


  • Oklahoma City, OK
    Ssm Health Care Of Oklahoma- Inc.
  • Tulsa, OK
    Oklahoma Cancer Specialists and Research Institute


  • Salem, OR
    Oregon Oncology Specialists


  • Gettysburg, PA
    PCSRI - Gettysburg
  • York, PA
    Cancer Care Associates of York

South Carolina

  • Greenville, SC
    Bon Secours (Greenville) - St. Francis Cancer Center

South Dakota

  • Sioux Falls, SD
    Sanford Health
  • Sioux Falls, SD
    Avera Cancer Institute


  • Houston, TX
    Oncology Consultants
  • Sugar Land, TX
    Lumi Research


  • Salt Lake City, UT
    Utah Cancer Specialists


  • Fredericksburg, VA
    Hematology Oncology Associates of Fredericksburg


  • Bellingham, WA
  • Olympia, WA
    Vista Oncology
  • Spokane, WA
    Cancer Care Northwest
  • Tacoma, WA
    Northwest Medical Specialties


  • Appleton, WI
  • La Crosse, WI
    Gundersen Health System
This Study is Open To:
  • People with the following may be eligible:
  • 55 years of age or older with locally advanced, or solid tumor with AXIN1 or APC mutation.
  • People with an APC mutation with colorectal cancer must not have a RAS / RAF mutation.
  • Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic treatment, or are ineligible for standard therapy.
  • Have measurable disease.
This Study is Not Open To:

The following people are not eligible:

  • People who received treatment with MEK inhibitor drug must wait at least 2 months before the first dose of REC-4881.
  • People with heart disease measured by echocardiogram (ECHO) or MUGA scan.